Related Experiment Video
Updated: Jun 16, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Unveiling the complexity of nonobstructive hypertrophic cardiomyopathy
Leopoldo Ordine1, Roberto Polizzi1, Grazia Canciello1
1Department of Advanced Biomedical Sciences, University Federico II, Via S Pansini 5, I-80131, Naples, Italy.
Insights
Nonobstructive hypertrophic cardiomyopathy (nHCM) presents diverse, serious risks, challenging its benign view. Personalized treatments and novel therapies are crucial for managing this complex heart condition.
Area of Science:
- Cardiology
- Genetics
- Internal Medicine
Background:
- Hypertrophic cardiomyopathy (HCM) is a genetic heart disorder with obstructive (oHCM) and nonobstructive (nHCM) forms.
- nHCM exhibits diverse morphologies and hemodynamic traits, unlike the defined obstruction in oHCM.
- nHCM's complexities, including apical hypertrophy and potential mid-ventricular obstruction, challenge its perception as a benign condition.
Purpose of the Study:
- To critically analyze the pathophysiology of nHCM.
- To evaluate current and emerging therapeutic strategies for nHCM.
- To provide guidance on contemporary management approaches for nHCM.
Main Methods:
- Literature review and critical analysis of pathophysiological mechanisms.
- Evaluation of current treatment options and emerging therapies.
- Assessment of diagnostic and therapeutic strategies for nHCM.
Main Results:
- nHCM presents diverse morphologies (apical hypertrophy, reverse septal curvature) with risks like LV aneurysms, arrhythmias, and thromboembolism.
- Symptoms in nHCM are often linked to diastolic and microvascular dysfunction.
- Traditional heart failure therapies show limited benefit, necessitating personalized treatment approaches.
Conclusions:
- nHCM is a complex condition requiring improved diagnostic and therapeutic strategies.
- Personalized management, including comorbidity optimization and assessing microvascular dysfunction, is warranted.
- Emerging therapies like myosin inhibitors and gene therapies show potential but require further investigation for nHCM applicability.
Abstract:
Hypertrophic cardiomyopathy (HCM) is a genetic heart disorder defined by the presence of a maximal wall thickness of at least 15 mm with two main forms: obstructive (oHCM) and nonobstructive (nHCM). While oHCM is characterized by left ventricular (LV) outflow tract obstruction (LVOTO), nHCM lacks this feature and shows significant variability in its hemodynamic and anatomical traits. In nHCM, LV hypertrophy (LVH) presents diverse morphologies, including apical hypertrophy and reverse septal curvature, the latter potentially causing mid-ventricular obstruction and near-complete LV emptying. Apical hypertrophy is associated with the risk of LV aneurysms, potentially leading to arrhythmias and thromboembolism. These findings challenge the belief that nHCM is a more benign phenotype than oHCM and highlight the necessity for improved diagnostic and therapeutic strategies. Symptoms in nHCM, such as fatigue and dyspnea, are often attributed to diastolic dysfunction, whereas symptoms like angina are attributed to microvascular dysfunction. However, current treatment options remain limited, as traditional heart failure therapies frequently fail to provide substantial benefits. Given its heterogeneity, a more personalized treatment approach is warranted, including optimizing comorbidities, assessing coronary microvascular dysfunction, and considering alternative pharmacologic strategies. Emerging therapies, such as myosin inhibitors mavacamten and aficamten, target sarcomeric hypercontractility and show promise in early trials, but their clinical impact on nHCM is still under investigation. Gene therapies also hold potential, though their applicability to nHCM is limited by the high rate of mutation-negative cases and the potential irreversibility of advanced disease states. This review critically analyzes the pathophysiological mechanisms of nHCM, evaluates current and emerging therapeutic strategies, and provides guidance on contemporary management approaches for this complex and often underrecognized condition.
Related Concept Videos
Pathophysiology of Heart Failure
Structure of Cardiac Muscles
Compared to skeletal muscles, cardiac muscle cells are small and mostly have a single nucleus. Additionally, they are usually...
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
Pathophysiology of Cardiac Performance

